

Not for release to US wire services or distribution in the United States

Next Science raises A\$10M institutional placement¹ and launches A\$5M SPP

Key points

- A\$10M (before costs) institutional placement completed¹ to support commercial rollout and further clinical program development
- Strong endorsement of the opportunity offered by Next Science's Xbio™ technology and product suite
- Share Purchase Plan to be launched on 4 March 2022 to raise up to an additional A\$5m (before costs)

Sydney, Australia Thursday, 24 February 2022, Next Science Limited (ASX:NXS) (**Next Science** or the **Company**) is pleased to announce that it has successfully completed a two tranche placement to institutional and sophisticated investors raising A\$10M (before costs) (**Placement**)¹. The Placement received strong support from existing and new eligible investors and was managed by Canaccord Genuity and Wilsons.

Approximately 11.1 million shares will be issued under the Placement (**New Shares**), equivalent to 5.6% of Next Science's total current shares on issue. The Placement is comprised of:

- A\$6.0 million raised within Next Science's placement capacity under ASX Listing Rule 7.1 (**Tranche 1**); and
- A\$4.0 million commitment from major shareholder, Mr. Lang Walker, with completion conditional upon shareholder approval (**Tranche 2**), pursuant to ASX Listing Rule 10.11 as Mr. Walker is the beneficial owner of around 40% of Next Science's issued capital.

Both tranches of the Placement are priced at A\$0.90 per share (**Offer Price**).

Funds raised from the Placement will be used to provide working capital to: accelerate the growth profile of the business and invest in sales and marketing; invest in clinical studies to provide further evidence of the efficacy of XPERIENCE™; and strengthen the balance sheet and provide working capital flexibility.

Next Science's Managing Director, Judith Mitchell said, "I am delighted with the strong level of support for the placement and I wish to thank existing shareholders for their continued support and welcome new shareholders to our register.

We are pleased to offer eligible shareholders the opportunity to participate in the capital raising via the SPP at the same price as institutional and sophisticated investors."

The Offer Price represents a 12.6% discount to the closing price of Next Science shares on the ASX on 22 February 2022, being A\$1.03 per share, and a 15.5% discount to the five-day VWAP of A\$1.07 as at the same date.

1. A\$4M of Placement conditional on shareholder approval at AGM in May 2022

Shares issued under the Placement will rank equally with existing Next Science ordinary shares on issue. Settlement of Tranche 1 of the Placement will take place on Wednesday, 2 March 2022, with allotment of the new shares expected to occur on Thursday, 3 March 2022. Trading of these shares is expected to commence on ASX on Thursday, 3 March 2022.

The settlement and issue of shares to Mr. Walker as part of Tranche 2 of the Placement is subject to shareholder approval and if approved, will occur after the annual general meeting which is expected to be held on 27 May 2022.

Share Purchase Plan

Next Science will offer existing eligible shareholders the opportunity to participate in a SPP to raise up to A\$5M (before costs). Existing shareholders of the Company who:

- (i) have a registered address in Australia and New Zealand as at 7.00pm (Sydney time) on 23 February 2022; and
- (ii) are not in the United States or acting for the account or benefit of a person in the United States,

will be eligible to participate in the SPP.

The SPP will provide each eligible shareholder with the opportunity to apply for up to A\$30,000 worth of new shares at the lower of:

- (i) the Offer Price (being A\$0.90); and
- (ii) the price that is a 2% discount to the VWAP of Next Science shares on the ASX over the five trading days up to, and including, the closing date of the SPP (rounded down to the nearest cent).

In the event of oversubscriptions, the SPP will be subject to a scale back of applications.

Shares issued under the SPP will rank equally with existing Next Science fully paid ordinary shares on issue.

The SPP offer document (**Offer Booklet**) containing further details of the SPP will be released on the ASX separately and is expected to be dispatched to all eligible shareholders in Australia and New Zealand on or about Friday, 4 March 2022, being the date on which the SPP will open.

Capital Raising Indicative Timetable**

Event	Date 2020
Record date for eligible shareholders to subscribe for New Shares via the SPP Offer	7.00pm (Sydney time) Wednesday 23 February
Announcement of SPP	Thursday, 24 February
Settlement of the Institutional Placement	Wednesday, 2 March
Issue of New Shares under the Institutional Placement	Thursday, 3 March

Trading of New Shares issued under the Institutional Placement commences on ASX	Thursday, 3 March
SPP Offer Booklet dispatched to shareholders	on or about Friday, 4 March
SPP Offer opens	Friday, 4 March
SPP Offer closes	Wednesday, 23 March unless extended
Announcement of results of SPP Offer	Monday, 28 March
Issue of New Shares under the SPP Offer	Tuesday, 29 March
Dispatch of holding statements and normal trading of New Shares issued under the SPP Offer	Tuesday, 29 March
Shareholder meeting to approve issue of shares to Next Science substantial holder, Mr. Lang Walker	Friday, 27 May

*** These dates are indicative only and are subject to change. Next Science reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, Next Science reserves the right to extend the Closing Date, accept late applications under the SPP Offer (either generally or in particular cases), and to withdraw or vary the Placement or SPP Offer without prior notice. Any extension of the closing date will have a consequential effect on the date for the allotment and issue of New Shares. The timetable in respect of the underwritten component of the Placement can only be amended by Next Science with the agreement of the underwriter.*

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

Approved and authorised for release by Next Science's Board of Directors.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may", and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws. Shares under the SPP will not be offered or sold to persons resident in the United States.